NPC1L1 knockout protects against colitis-associated tumorigenesis in mice

BMC Cancer

Jianming He²  Hyunsu Shin²  Xing Wei²  Anil Kumar G Kadegowda²  Rui Chen¹  Sandy Krystal Xie² 

[1] Department of Pathology, Chongqing Cancer Hospital, Chongqing 400030, People’s Republic of China

[2] Department of Animal and Avian Science, University of Maryland, College Park 20742, MD, USA

关键词: p53;    β-catenin;    Cholesterol;    Tumorigenesis;    Colorectal cancer;    NPC1L1;   

Others  :  1161241
DOI  :  10.1186/s12885-015-1230-0

 received in 2014-09-23, accepted in 2015-03-19,  发布年份 2015

【 摘 要 】

Background

Colorectal cancer is strongly associated with lipid metabolism. NPC1L1, a sterol transporter, plays a key role in modulating lipid homeostasis in vivo. Its inhibitor, ezetimibe, began to be used clinically to lower cholesterol and this caused the great debate on its role in causing carcinogenesis. Here we explored the role of NPC1L1 in colorectal tumorigenesis.

Methods

Wild-type mice and NPC1L1^−/− (NPC1L1 knockout) mice were treated with azoxymethane (AOM)-dextran sodium sulfate (DSS) to induce colitis-associated colorectal tumorigenesis. Mice were sacrificed 10, 15, 18 or 20 weeks after AOM treatment, respectively. Colorectal tumors were counted and analyzed. Plasma lipid concentrations were measured using enzymatic reagent kit. Protein expression level was assayed by western blot.

Results

NPC1L1^−/− mice significantly had fewer tumors than wild-type. The ratio of malignant/tumor in NPC1L1^−/− mice was significantly lower than in wild-type 20 weeks after AOM-DSS treatment. NPC1L1 was highly expressed in the small intestine of wild-type mice but its expression was undetectable in colorectal mucous membranes or tumors in either group. NPC1L1 knockout decreased plasma total cholesterol and phospholipid. NPC1L1^−/− mice had significant lower intestinal inflammation scores and expressed inflammatory markers p-c-Jun, p-ERK and Caspase-1 p20 lower than wild-type. NPC1L1 knockout also reduced lymphadenectasis what may be caused by inflammation. NPC1L1 knockout in mice decreased β-catenin in tumors and regulated TGF-β and p-gp in adjacent colons or tumors. There was not detectable change of p53 by NPC1L1 knockout.

Conclusions

Our results provide the first evidence that NPC1L1 knockout protects against colitis-associated tumorigenesis. NPC1L1 knockout decreasing plasma lipid, especially cholesterol, to reduce inflammation and decreasing β-catenin, p-c-Jun and p-ERK may be involved in the mechanism.

【 授权许可】

   
2015 He et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
• [2]Bardou M, Barkun AN, Martel M: Obesity and colorectal cancer. Gut 2013, 62:933-947.
• [3]Tornberg SA, Holm LE, Carstensen JM, Eklund GA: Risks of cancer of the colon and rectum in relation to serum cholesterol and beta-lipoprotein. N Engl J Med 1986, 315:1629-1633.
• [4]Ulmer H, Borena W, Rapp K, Klenk J, Strasak A, Diem G, et al.: Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br J Cancer 2009, 101:1202-1206.
• [5]Jia L, Betters JL, Yu L: Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. Annu Rev Physiol 2011, 73:239-259.
• [6]Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al.: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359:1343-1356.
• [7]Peto R, Emberson J, Landray M, Baigent C, Collins R, Clare R, et al.: Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008, 359:1357-1366.
• [8]Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA: Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J Biol Chem 2005, 280:12710-12720.
• [9]Jia L, Ma Y, Rong S, Betters JL, Xie P, Chung S, et al.: Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis. J Lipid Res 2010, 51:3135-3144.
• [10]Neufert C, Becker C, Neurath MF: An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc 2007, 2:1998-2004.
• [11]Thaker AI, Rao MS, Bishnupuri KS, Kerr TA, Foster L, Marinshaw JM, et al.: IDO1 Metabolites Activate beta-catenin Signaling to Promote Cancer Cell Proliferation and Colon Tumorigenesis in Mice. Gastroenterology 2013, 145:416-425.
• [12]Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, et al.: A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009, 15:1016-1022.
• [13]He JM, Wang FC, Qi HB, Li Y, Liang HJ: Down-regulation of alphav integrin by retroviral delivery of small interfering RNA reduces multicellular resistance of HT29. Cancer Lett 2009, 284:182-188.
• [14]Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, et al.: Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303:1201-1204.
• [15]Temel RE, Tang W, Ma Y, Rudel LL, Willingham MC, Ioannou YA, et al.: Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest 2007, 117:1968-1978.
• [16]Flores MB, Rocha GZ, Damas-Souza DM, Osorio-Costa F, Dias MM, Ropelle ER, et al.: Obesity-induced increase in tumor necrosis factor-alpha leads to development of colon cancer in mice. Gastroenterology 2012, 143:741-753. e741-744
• [17]Hu B, Elinav E, Huber S, Booth CJ, Strowig T, Jin C, et al.: Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci U S A 2010, 107:21635-21640.
• [18]Kamo N, Ke B, Ghaffari AA, Shen XD, Busuttil RW, Cheng G, et al.: ASC/caspase-1/IL-1beta signaling triggers inflammatory responses by promoting HMGB1 induction in liver ischemia/reperfusion injury. Hepatology 2013, 58:351-362.
• [19]Worsley MA, Allen CE, Billinton A, King AE, Boissonade FM: Chronic tooth pulp inflammation induces persistent expression of phosphorylated ERK (pERK) and phosphorylated p38 (pp 38) in trigeminal subnucleus caudalis. Neuroscience 2014, 269:318-330.
• [20]Xiao C, Wang RH, Lahusen TJ, Park O, Bertola A, Maruyama T, et al.: Progression of chronic liver inflammation and fibrosis driven by activation of c-JUN signaling in Sirt6 mutant mice. J Biol Chem 2012, 287:41903-41913.
• [21]Lee SH, Hu LL, Gonzalez-Navajas J, Seo GS, Shen C, Brick J, et al.: ERK activation drives intestinal tumorigenesis in Apc(min/+) mice. Nat Med 2010, 16:665-670.
• [22]Xu YM, Zhu F, Cho YY, Carper A, Peng C, Zheng D, et al.: Extracellular signal-regulated kinase 8-mediated c-Jun phosphorylation increases tumorigenesis of human colon cancer. Cancer Res 2010, 70:3218-3227.
• [23]Biswas A, Liu YJ, Hao L, Mizoguchi A, Salzman NH, Bevins CL, et al.: Induction and rescue of Nod2-dependent Th1-driven granulomatous inflammation of the ileum. Proc Natl Acad Sci U S A 2010, 107:14739-14744.
• [24]Tanizawa Y, Bando E, Kawamura T, Tokunaga M, Sasaki K, Terashima M: Intramucosal gastric cancer with fifteen metastatic lymph nodes: report of a case. Hepatogastroenterology 2012, 59:2233-2237.
• [25]Wang J, Chu BB, Ge L, Li BL, Yan Y, Song BL: Membrane topology of human NPC1L1, a key protein in enterohepatic cholesterol absorption. J Lipid Res 2009, 50:1653-1662.
• [26]Li J, Liu Y, Wang B, Xu Y, Ma A, Zhang F, et al.: Myeloid TGF-beta signaling contributes to colitis-associated tumorigenesis in mice. Carcinogenesis 2013, 34:2099-2108.
• [27]Mochida Y, Taguchi K, Taniguchi S, Tsuneyoshi M, Kuwano H, Tsuzuki T, et al.: The role of P-glycoprotein in intestinal tumorigenesis: disruption of mdr1a suppresses polyp formation in Apc(Min/+) mice. Carcinogenesis 2003, 24:1219-1224.
• [28]Goldstein I, Ezra O, Rivlin N, Molchadsky A, Madar S, Goldfinger N, et al.: p53, a novel regulator of lipid metabolism pathways. J Hepatol 2012, 56:656-662.
• [29]Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, et al.: Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 2013, 23:634-646.
• [30]Chan DC, Watts GF, Wang J, Hegele RA, van Bockxmeer FM, Barrett PH: Variation in Niemann-Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men. Clin Endocrinol (Oxf) 2008, 69:45-51.